Sanofi

Vib Vzw

Vrije Universiteit Brussel

Life Sciences Research Partners Vzw

Corentin Herbert

Francis Blanche

Gilbert Lassalle

Vincent Mikol

Chantal Alcouffe

Peter Carmeliet

Béatrice Cameron

Nicolas Baurin

Tarik Dabdoubi

Reinhard Kirsch

Philippe Duchaussoy

Joost Schymkowitz

Frederic Rousseau

Françoise Bono

Pierre Fons

Pierre Alexandre Driguez

Elisabeth Remy

Frederik De Smet

Frédéric Rousseau

Gilbert Lassale

Pierre-François Berne

The invention relates to the use of compounds corresponding to formula (I) in which Rand Rtogether form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to one of the formulae (A), (B) and (C) in which the wavy lines represent the phenyl nucleus to which Rand Rare attached, or of a pharmaceutically acceptable salt thereof, for preparing a medicament for the treatment of bladder cancer. 

Therapeutic use of imidazopyridine derivatives

The invention relates to compounds corresponding to formula (I):  in which the wavy lines represent the phenyl nucleus to which Rand Rare attached. Preparation process and therapeutic use.

Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof

The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.

Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor

The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: Ris an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, Ris an OSOor hydroxyl group, Ris an alkyl, cycloalkyl, or alkyl-cycloalkyl group, Ris a disaccharide having Formula (II), Ris a disaccharide having Formula (III), and Ris a disaccharide having Formula (IV), where R, R, and Rare OSOor hydroxyl groups. The invention further relates to the preparation of said octasaccharides and to the therapeutic use thereof. 

FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof

Indolizine derivatives, process for the preparation thereof and therapeutic use thereof

Growing community of inventors

Paris, France

Corentin Herbert